Contact us at 914-666-4665

Dr. Daniel Cameron

Board-certified physician with 38+ years specializing in Lyme disease and tick-borne illnesses. Past President of ILADS (International Lyme and Associated Diseases Society) and first author of ILADS treatment guidelines. Dr. Cameron operates a solo practice focused on patient advocacy and evidence-based Lyme disease treatment. He is the author of 1,100+ articles spanning diagnosis, treatment, co-infections, and recovery from tick-borne illnesses. His work challenges conventional approaches that often leave patients undiagnosed or undertreated, emphasizing clinical judgment over rigid adherence to testing criteria that frequently produce false negatives.

Dr. Daniel Cameron
Borrelia miyamotoi FDA test

Where Is the FDA Test for Borrelia miyamotoi?

The FDA Testing Gap for Emerging Tick-Borne Diseases Where is the Borrelia miyamotoi FDA test? If the FDA gets its way, physicians would only have access to diagnostic tests for tick-borne diseases that are FDA approved. This would eliminate “specialty labs,” and severely restrict a clinician’s ability to diagnose Lyme disease, as well as other […]

Where Is the FDA Test for Borrelia miyamotoi? Read More »

Lyme disease: One size does not fit all

A read of the International Lyme and Associated Diseases Society (ILADS) 2014 evidence based guidelines says otherwise.  The ILADS guidelines focus on the risk of poor outcomes such as chronic neurologic Lyme disease, Lyme encephalopathy, and post-Lyme disease syndrome. The ILADS guidelines highlight the poor evidence using the Institute of Medicine’s recommended evidence grading system.  The

Lyme disease: One size does not fit all Read More »

Is your fibromyalgia patient a candidate for Lyme disease treatment?

After 37 years treating Lyme disease, I’ve seen men and women originally diagnosed with fibromyalgia find symptom relief once given antimicrobial treatment. The symptom overlap between these conditions creates diagnostic challenges that can lead to missed or delayed diagnosis when infection is the underlying cause. Symptom Overlap Between Fibromyalgia and Lyme Disease Fibromyalgia and Lyme

Is your fibromyalgia patient a candidate for Lyme disease treatment? Read More »

draft post

The task force by Executive Order must submit an action plan by February 15, 2015, outlining specific steps on how to implement a national strategy to combat antibiotic resistance and accelerate research and development on new antibiotics by 2020. The task force will be led by the secretaries of Health and Human Services, the Department

draft post Read More »

Obama plan to fight antibiotic resistance may limit treatment for Lyme disease

The task force by Executive Order must submit an action plan by February 15, 2015, outlining specific steps on how to implement a national strategy to combat antibiotic resistance and accelerate research and development on new antibiotics by 2020. The task force will be led by the secretaries of Health and Human Services, the Department

Obama plan to fight antibiotic resistance may limit treatment for Lyme disease Read More »

Congratulations Congressman Chris Gibson, NY 19th CD, on passage of the Lyme disease bill

Congratulations are also in order for Congressman Chris Smith, NJ for all his years of support and work on making this bill. Congressman Sean Maloney, NY and Wolf, VA are to be thanked for their leadership as well.  Steve Bulger, District Director, Congressman Chris, Gibson – NY 19th CD, 518-610-8133 (office) Thanks are also in order

Congratulations Congressman Chris Gibson, NY 19th CD, on passage of the Lyme disease bill Read More »

Lyme disease patients may struggle with depression

One study found that more than 1/3 of patients with chronic neurologic Lyme disease suffered from depression, in addition to fatigue, headaches, poor concentration, lightheadedness, and joint pain. While depression is not uncommon in patients with chronic illness, it does seem to be more prevalent among patients with Lyme disease, according to Dr. Robert Bransfield,

Lyme disease patients may struggle with depression Read More »

Borrelia miyamotoi FDA test

LabCorp Western Blot Policy: What Changed and Why It Matters

When LabCorp Restricted Western Blot Access In 2014, LabCorp announced a policy change that sent shockwaves through the Lyme disease community: physicians would no longer be able to order Western blot testing for Lyme disease unless the initial screening test (ELISA or IFA) was positive or equivocal. This meant that if a patient’s screening test

LabCorp Western Blot Policy: What Changed and Why It Matters Read More »

Doxycycline Shortage and Lyme Disease: Lessons From the Hudson Valley

Senator Schumer Addresses Doxycycline Shortage During Peak Lyme Season Senator Schumer addressed the growing shortage of doxycycline during an August 12, 2004 press conference in the Hudson Valley, New York. At the time, Lyme disease cases were rising sharply across the region, raising concern about access to one of the most commonly prescribed antibiotics for

Doxycycline Shortage and Lyme Disease: Lessons From the Hudson Valley Read More »